Introduction
The evolution of the HIV epidemic, in particular with expansion of access to antiretroviral therapy, has resulted in an increase in the number of people living with HIV or AIDS (PLWHA) in middle and old age. Over age 50, this population has doubled since 1995 and, in 2013, UNAIDS estimated that it was between 4.0 and 4.5 of the 35 million PLWHA. 1 At these older ages, the risks and management of non-communicable diseases become increasingly relevant 2 , including of cancers that are neither AIDS-defining nor HIV-associated. The latter cancers now constitute the majority of cancers in PLWHA in more developed settings, 2 which has spurred their epidemiologic and clinical research. affected by HIV and breast cancer. 7 The HIV-positive breast cancer patient population is expected to further increase in absolute size over the coming decades, assuming that access to HAART continues.
It is thus timely to build the epidemiologic evidence base for breast cancer in WLWHA. Pertinent issues are diverse 10 and have begun to be addressed, 11, 12 ranging from breast cancer awareness and early breast cancer detection in WLWHA, to clinical co-management of two diseases. The need for research on these issues will in part depend on the number of WLWHA affected by breast cancer. In the present study, amongst the 16 million WLWHA aged 15 years and over, we provide the first global estimates of the number of HIV-positive women who were newly diagnosed with breast cancer in 2012. We also examine their age and geographical distribution worldwide, and identify the settings where HIV-positive breast cancer patients constitute a substantial proportion of the breast cancer patient profile. Finally, a systematic literature review was conducted to assess the consistency of our estimates with published reports of HIV-positive breast cancer patients.
Methods

Breast cancers in WLWHA
We estimated the number of new breast cancers occurring in WLWHA aged 15 years and over in 4 2012, overall, by age, and UN sub-region. The basis of the primary estimation, which will be considered later, was to assume that there was no direct or indirect association between HIV and breast cancer risk, thus the number of HIV-positive breast cancers was calculated as the total number of breast cancers multiplied by the corresponding HIV prevalence in a given age-country stratum.
For each country, age-specific breast cancer incidence (number of new cases) in 2012 was sourced from IARC GLOBOCAN. 13 15 Based on these latter observations, we also provide a lower worldwide estimate.
Literature review
To assess the degree of consistency of the present estimates with the previous literature, we systematically reviewed studies that have documented the occurrence of breast cancer in HIV-positive women either as part of breast cancer case series or breast cancers occurring in HIV cohorts. The review search identified articles containing the terms "cancer" and "HIV", through a literature search conducted with the US National Library of Medicine PubMed on 18 th October 2017, and, so as to be relevant to the HAART era, it was restricted to articles published in English after 1 st January 2000.
This search yielded 760 results after excluding reviews and commentaries. These 760 publications were screened and deemed eligible if they reported on at least five HIV-positive women with breast cancer.
Statistical analysis
The GATHER checklist was followed for these global estimates (Supplementary Table 2 We also considered the impact of uncertainties in the estimates of WLWHA and in the breast cancer -HIV association. For the former, uncertainty in the number of WLWHA at older ages is relatively small, of the order of ±5% 1 , and for the latter, a 42% deficit of breast cancer found in the US HIV population 15 . We therefore also estimated a lower bound on the number of breast cancers in WLWHA, by multiplying estimates by (1-0.05)(1-0.42). An upper bound was not calculated because there is no suggestion of an excess of breast cancer in WLWHA.
Results
Global estimates of breast cancer in WLWHA
In 2012 worldwide, there were an estimated 16.0 million WLWHA worldwide (aged 15+ years). The highest HIV-prevalence proportions were in sub-Saharan Africa, which had 12. Figure 1 ).
The age-structure of the WLWHA population and corresponding age-specific breast cancer incidence rates are shown in Figure 2 , for eight sub-regions were there were at least 100,000 WLWHA over age 15 years, and all other sub-regions combined. The overall pattern is one of relatively low breast cancer incidence rates in regions with large populations of WLWHA. For example, in Eastern Africa, the subregion with most WLWHA, breast cancer incidence rates were relatively low compared to world averages, giving an estimated 1563 breast cancers in HIV-positive women. Because breast cancer incidence rates were higher in Southern Africa and, at older ages, in Western Africa, those two sub- Figure 4 . These proportions are very low (<1%) in every sub-region, except, under age 50 in the Caribbean (1%), in Middle, Western and Eastern Africa (4-6%), and Southern Africa (26%), and, over age 50, in Eastern (3.2%) and Southern Africa (7.6%). women (median 53 years). HIV-positive breast cancer patients were diagnosed at younger ages than their HIV-negative counterparts, in line with our global estimates.
Literature review
Discussion
Using country-level estimates of HIV prevalence and breast cancer incidence from UNAIDS and IARC-GLOBOCAN respectively, we estimated the worldwide burden of new breast cancers in WLWHA to be 6300 in 2012, 75% of which occurred in Southern, Eastern and Western Africa.
Because the HIV-positive population has a young age structure, 75% of this patient population was diagnosed at ages 35-54 years. Although Southern Africa has a smaller population of WLWHA than Eastern Africa, the two sub-regions each had one-quarter of patients due to higher breast cancer incidence rates in the latter sub-region. Under the scenario that a deficit of breast cancer occurs in WLWHA, as has been observed in the US, the worldwide burden would be nearer 3600.
The size of this patient population is already appreciable in absolute terms. Ranking countries worldwide by the number of incident breast cancers in 2012, the WLWHA population would rank 38 th out of 184 countries (i.e. 80 th percentile), with a total breast cancer incidence similar to that of Sweden.
In comparison with the AIDS defining malignancy, Kaposi Sarcoma (KS), for every 5 women with KS, there were an estimated 2 breast cancers in WLWHA. 17 Further, this absolute incidence burden is expected to increase in size over the next 1-2 decades, owing to ageing of the current HIV population and to an additional 1 million women newly diagnosed with HIV each year. However, we deliberately did not attempt to predict the future burden, because of the uncertainties around several parameters, including continued access to HAART and the breast cancer risk factor profile of the young HIVpositive population.
These global estimates of the HIV-positive breast cancer patient population are subject to an assumption of no HIV-breast cancer risk association. This assumption is supported by three subSaharan African studies, where the HIV prevalence among breast cancer patients was similar to that of the age-matched source population. [7] [8] [9] These studies were conducted in South Africa, and included patients diagnosed both in the pre-HAART 9 and post-HAART era 7, 8 . Lending further plausibility to this assumption, for a given setting, our estimated HIV-prevalence among breast cancer patients was consistent with the published studies from that sub-region, as reviewed. Together, these suggest that the deficit of breast cancer in HIV+ women in the US may not be a universal feature of WLWHA.
However, further studies on the HIV-breast cancer risk link in HIV endemic areas are needed, as few have been able to examine how incidence is affected by HIV directly or through indirect pathways, e.g. due to altered distributions of breast cancer risk factors such as parity, age at first birth and breast feeding. The US results may also differ to African findings as the former are set within populations regularly screened for breast cancer, some of which are over-diagnoses, whereas in most HIV endemic sub-regions almost all breast cancer patients are diagnosed at symptomatic stages.
The estimates are also limited by uncertainties in HIV prevalence data and, especially, in breast cancer incidence data. GLOBOCAN estimates have larger uncertainties in some HIV-endemic countries in sub-Saharan Africa as the region has few population-based or other cancer registries. Notably, of 54
African countries/territories listed in GLOBOCAN, only seven had high-quality data (four in North
Africa and three in countries with a high HIV prevalence). The large populations of Nigeria, South
Africa and Ethiopia had lower quality national cancer incidence data, and in twenty, mostly smaller, countries data from neighbouring countries were used to generate national cancer incidence estimates.
Nevertheless, the GLOBOCAN estimates are well-recognized as the most accurate data-driven estimates currently available.
An opportunity and need exists to improve outcomes for HIV-positive breast cancer patients facing two chronic diseases. Where the majority of this patient population lies, in sub-Saharan Africa, breast cancer is typified by an advanced stage distribution at diagnosis and poor survival. 18 Prolonged intervals to diagnosis are a major contributor to late stage, 19 but for WLWHA, their established contact with the health system for HAART medication offers an opportunity to educate about breast and other cancers, to encourage early presentation, and ensure referral, diagnosis and treatment not only of AIDS-associated malignancies, but also of other common cancers. Similar to the integration of cervical cancer screening into HIV clinics, 20 this contact provides a valuable opportunity for breast health awareness, education and early presentation in order to minimize delays to diagnosis, achieve However, in the context of the younger patient and the sub-Saharan African setting, benign breast disease, tuberculosis and, occasionally, Kaposi sarcoma of the breast add to diagnostic challenges.
Turning to higher-income countries, attendance of breast cancer screening amongst WLWHA was higher than that of the general population in France, 21 but lower in Ontario, Canada, 22 thus a setting-specific evaluation of early-diagnosis interventions needed in WLWHA is warranted.
In the sub-Saharan African region, where 75% of HIV-positive breast cancer patients live, breast cancer survival rates are generally some of the lowest worldwide. For HIV-positive and HIV-negative women combined, 5-year breast cancer survival estimates are 24% in Nigeria, 46% in Ethiopia, and 64%/80% in black/white South Africans, [23] [24] [25] [26] which compare to over 85% in the US. 27 Moreover, HIVpositive breast cancer patients have lower survival than their setting-matched HIV-negative counterparts. A study in the US revealed excess all-cause mortality in HIV-positive breast cancer patients relative to women with only one of the two diseases. 28 Moving to sub-Saharan Africa, there are two relevant survival studies. In the Uganda Cancer Cohort, 24 HIV-positive women with breast cancer had 2-fold increased mortality rates (hazard ratio 2.04; 95% CI 0.76, 5.47) compared to HIVnegative breast cancer women, 29 whilst in 88 HIV-positive breast cancer patients in Soweto, a nonsignificant increased mortality rate was seen (hazard ratio 1.4) relative to their HIV-negative counterparts. 30 In addition to further survival studies, research needs to address side-effects and survivorship, with relevant studies currently underway 12, 19 . Clinically, concerns have been raised related to delays in initiating primary or adjuvant chemotherapy in highly immuno-suppressed patients, HAART-chemotherapy interactions, and a higher incidence of intolerance to, and side-effects of, chemotherapy, including chemotherapy-induced neutropenia 31 , which are often exacerbated in the HIV-positive cancer patient. 3 In palliative care patients in South Africa and Uganda, Selman et al.
found lower quality of life in HIV-positive patients than in cancer patients, and lack of psychosocial support mechanisms for the small proportion of women with both diagnoses. 32 Some countries such as Uganda have prioritized palliative care for HIV and cancer patients.
In conclusion, the estimated 6300 new breast cancer patients diagnosed in 2012 amongst women living with HIV is substantial. Research that addresses the impact of these combined comorbidities along the entire patient journey for both diseases is warranted in the settings we identified here.
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